ClinicalTrials.gg
RecruitingNCT06553339Updated Aug 14, 2024

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

A Phase 1 interventional study of Oral HS-10516 in Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-08-14.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in patients with VHL Syndrome Associated Tumors.

Read the detailed description

This is a Phase Ia/Ib open label multicenter study of HS-10516 in Chinese patients aged 18 years or older with VHL Syndrome Associated Tumors. HS-10516 as a single agent, is administrated orally once daily. The aim of phase Ia, a dose escalation study, is to identify the MTD/MAD of HS-10516. The goal of Phase Ib, a dose expansion study, is to evaluate the safety, pharmacokinetics and antitumor efficacy of HS-10516.

02

Conditions studied

  • Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma

Keywords

  • Von Hippel Lindau Syndrome
  • VHL Syndrome
  • RCC
  • pNET
  • CNS hemangioblastoma
03

In context

von Hippel-Lindau Disease

55 studies on the registry are indexed under von Hippel-Lindau Disease; 23 are open to participants now.

This study's planned enrollment of 60 is above the median of 28 across 31 interventional studies indexed under von Hippel-Lindau Disease.

Browse von Hippel-Lindau Disease studies →

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female from 18 to 80 year-old
  2. Patients with advanced clear cellrenal cell carcinoma or von Hippel-Lindau Syndrome associated tumors
  3. Has an performance status of 0-1
  4. Has a of ≥ 12 weeks
  5. Should use adequate measures throughout the study
  6. Females subject must not be pregnant at screening
  7. Has the ability to understand and willingness to sign a written before the performance of the study.

Exclusion criteria

Exclusion Criteria:

  1. Recieved or being received treatment as follows:

    1. Hypoxia-induced factor inhibitors
    2. Traditional Chinese medicine indicated for tumors within 2 weeks prior to the first dose of study treatment.
    3. Cytotoxic chemotherapeutic drugs, drugs or other systematic anti-tumor therapies within 3 weeks before the first dose of study treatment
    4. Colony-stimulating factors (CSFs) within 4 weeks before the first dose of study treatment
    5. Local radiotherapy within 2 weeks prior to the first dose of study treatment; more than 30% of bone marrow radiotherapy or large-area irradiation within 4 weeks before the first dose of study treatment.
    6. Major surgery within 4 weeks prior to the first dose of study treatment.
  2. Has a pulse oximetry reading less than 92% at screening, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
  3. Has failed to recover from a ≥ grade 2 adverse event due to prior anti-tumor therapy
  4. Has another or a history of another non-VHL syndrome associated malignancy
  5. Has inadequate bone marrow reserve or organ dysfunction
  6. Has a bleeding events or tendency within 1 month prior to the first dose of study treatment
  7. Has severe infections within 4 weeks prior to the first dose of study treatment
  8. Has digestive system diseases may influencing ADME of study drug
  9. Has a history of severe reaction, or proven allergic to HS-10516 or its metabolin
  10. Has any disease or condition would compromise subject safety or interfere with study assessments by investigator's decision
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Phase Ia dose escalation arm

    Participants will be assigned to pre-specified dose level to identify the MTD/MAD of HS-10516.

    Drug: Oral HS-10516

  • Experimental
    Phase Ib dose expansion arm 1

    Participants with VHL Syndrome associated RCC, whose lesions diameter ≤ 3 cm.

    Drug: Oral HS-10516

  • Experimental
    Phase Ib dose expansion arm 2

    Participants with VHL Syndrome associated RCC, who could not be included in arm 1.

    Drug: Oral HS-10516

  • Experimental
    Phase Ib dose expansion arm 3

    Participants with VHL Syndrome associated non-RCC tumors.

    Drug: Oral HS-10516

Interventions

06

What researchers measure

Primary outcomes

  1. Phase Ia: MTD/MAD of HS-10516

    Maximum Tolerated Dose or Maximum Acceptable Dose determined by the Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period (first 35 days of dosing) in the Dose Escalation Phase

    Time frame: Approximately 2 months

  2. Phase Ib: Objective Response Rate (ORR) by Independent Review Committee (IRC)

    ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. ORR will be assessed by IRC.

    Time frame: Approximately 1 year

Secondary outcomes

  1. The Number of Participants with Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.

    Time frame: Approximately 2 years

  2. Observed maximum plasma concentration (Cmax) of HS-10516

    Cmax will be obtained following administration of the first dose of HS-10516 during first 2 cycles.

    Time frame: Approximately 2 months

  3. Time to reach maximum plasma concentration (Tmax) of HS-10516

    Tmax will be obtained following administration of the first dose of HS-10516 during first 2 cycles.

    Time frame: Approximately 2 months

  4. Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) following the first dose of HS-10516

    Area under the plasma concentration versus time curve from time zero to the last sampling time when the concentration was no less than the lower limit of quantification (LLQ). AUC0-t was calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Approximately 1 year

  5. ORR by investigators/IRC per system

    ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Approximately 1 year

  6. Disease Control Rate (DCR) by investigators/IRC per system

    DCR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) or a stable disease (SD) of 8 weeks or longer based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Approximately 1 year

  7. Duration of Response (DoR) by investigators/IRC per system

    DoR is defined as the time from the date of first documented CR or PR, assessed by investigator and based on RECIST v. 1.1, to the documented date of progressive disease (PD) or death, whichever occurred first.

    Time frame: Approximately 1 year

  8. Progression Free Survival (PFS) by investigators/IRC per system

    PFS defined as the time from the date the participant started study drug to the date the participant experiences an event of disease progression or death.

    Time frame: Approximately 2 years

  9. Overall Survival (OS)

    OS defined as the time from the date the participant started study drug to death for any reason.

    Time frame: Approximately 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2024
First posted
Aug 14, 2024
StartActual
Jul 19, 2024
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2028
Last update
Aug 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06553339
Responsible party
Sponsor
First posted
Aug 14, 2024
Start date
Jul 19, 2024
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Aug 14, 2024

Study contacts

Kan Gong, PhD
Contact
kan.gong@bjmu.edu.cn
13910394281
Kan Gong, PhD
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HIF-2alpha Inhibitor HS-10516

Start the discussion